Key facts
- BioChest’s last known valuation is $3.0M (Sep 2025).
- It has raised $490K; the latest was Seed Round ($490K) in Sep 2025.
- Notable investors include Transpose Platform Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for BioChest
- ·The full record, as it builds
Funding rounds
No funding rounds for BioChest are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioChest
Developer of optimized and fine-tuned AI models designed for drug discovery. The company's system has various features, such as protein and enzyme design, antibody engineering, and small molecule discovery, enabling fast protein and enzyme design, antibody engineering, and small molecule discovery, used by companies to accelerate R&D.
- Sector
- Healthcare
- HQ
- Lewes, DE, United States
- Founded
- 2024
- Website
- biochestcloud.com/
- Ownership
- Privately Held (backing)
BioChest doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioChest shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioChest in its N-PORT filings yet. We sweep new filings monthly.